Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. IM1240 is the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4. Purple Biotech has an Investigational New Drug (IND) submission planned for 2026.
🌍 Purple Biotech Ltd. (PPBT) - Form 6-K Filing
Filing Date: 2025-10-29
Accepted: 2025-10-29 07:33:58
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: